A cute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children, constituting about 30% of all childhood cancers. Although the clinical, pathological, and immunophenotypic features of this disease have been well documented, the causes of most cases of children with ALL are unknown. [1] [2] [3] The biological mechanisms of ALL are complex and have not been fully clarified. It is generally considered that the interaction between genetic susceptibility and environmental exposures may play an important role in the etiology of ALL. [3] [4] [5] [6] It has been suggested that host polymorphisms may modify the individual's ability to respond to xenobiotics and maintain an intact genome in face of genotoxic stress. [7] Thus, polymorphisms in genes encoding xenobiotic-metabolizing enzymes may have determined susceptibility to cancer. Xenobiotics are activated mainly by the activities of cytochrome P450 (CYP450) family of enzymes and then converted into more hydrophilic forms under the catalysis of conjugation enzymes. CYP450 enzymes are involved in the metabolism of a wide range of drugs and potential xenobiotics. The most highly expressed subfamily is CYP3A, which includes the isoforms CYP3A4, CYP3A5, CYP3A7, and CYP3A43. CYP3A5 is responsible for the metabolism of more than 50% of clinically therapeutic drugs and a variety of endogenous compounds and pro-carcinogens. [8, 9] However, CYP3A5 polymorphism is more prevalent and shows significant differences in protein expression level between ethnic groups. [8, 10, 11] These variations may be due to genetic polymorphisms and by the modulation of CYP3A expression through various environmental factors and drug-drug interactions. Therefore, CYP3A5 may be an important genetic contributor to inter-individual and inter-racial differences in CYP3A-mediated metabolism. [8, 12] The most important functional single nucleotide polymorphism (SNP) in CYP3A5 gene is CYP3A5 * 3 6986A > G (rs776746). [13] CYP3A5 * 3 confers low CYP3A5 expression because of alternative mRNA splicing. This results in the incorporation of an intron sequence into the mature mRNA, and the production of a truncated protein due to premature termination of translation. [8] Thus, CYP3A5 * 3 genetic polymorphism may play a role in the risk of developing cancer. [14] [15] [16] The role of CYP3A5 * 3 polymorphism in the development of ALL in children has been extensively investigated, but reported with inconsistent results. To investigate the possible effect of CYP3A5 variant on the ALL risk through a more robust and powered analysis, we carried out a meta-analysis of case-control studies that examined the association between CYP3A5 * 3 genetic polymorphism and the risk of ALL in children.
METHODS

Identification and eligibility of relevant studies
The electronic PubMed, Elsevier, EMBASE, China Biological Medicine Database (CBM), China National Knowledge Infrastructure platform (CNKI), and Wanfang database were searched for articles published before October 2013 with the following search terms: Cytochrome P4503A5 or CYP3A5; polymorphism, variant, or mutation; leukemia or acute leukemia; children, childhood, or pediatric. Literature search included all languages. References of retrieved articles were also screened to identify additional publications.
The following were the inclusion criteria used for study selection: (1) Case-control study; (2) confirmed diagnosis for the case group according to the diagnosis criteria of ALL in children; (3) genotype frequency available in both cases and controls; and (4) genotype distribution in the control group was in agreement to Hardy-Weinberg equilibrium (HWE). Abstracts, case reports, commentary, and review articles were excluded. When the case-control study was included by more than one article using the same case series, we selected the one with the largest number of participants only.
Data extraction
The following information was collected about each included study: The first author, year of publication, country of origin, ethnicity, genotyping method, and genotype distribution. Two observers extracted the information from each study independently, and disagreements were resolved by discussion and the data were evaluated by a third reviewer.
Statistical analysis
We applied odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of association between CYP3A5 * 3 polymorphism and ALL risk in children. The χ 2 -based Q-statistic test was used to assess between-study heterogeneity and the degree of heterogeneity was quantified with I 2 metric. The result was considered significant when p < 0.05, in which case the random-effects model (DerSimonian-Laird) was used to calculate the pooled OR. Alternatively, the pooled OR was estimated using the fixed-effects model (Mantel-Haenszel). The inverted funnel plots were used to evaluate the publication bias. HWE in the control group for all studies was checked using the χ 2 test. All the p values were two-sided, and p < 0.05 was considered as statistically significant. All data analyses were performed with Review Manager v5.2 (The Cochrane Collaboration, Oxford, UK) and Stata v10.0 (Stata Corporation, College Station, TX, USA).
RESULTS
Study characteristics
We identified a total of 19 potentially relevant publications based on the literature search criteria. At the initial screening, nine articles were excluded; during further screening, five studies were excluded due to data duplication, data insufficiency, data error, and by assessing complication risk. Finally, five case-control studies including 1070 cases and 1125 controls met the inclusion criteria and were suitable for the meta-analysis. [17] [18] [19] [20] [21] A flow chart of the literature search and study selection is presented in Figure 1 . The countries in which these studies had been carried out include Denmark, Thailand, China, and Brazil. The cases had a confirmed diagnosis of ALL and the controls were healthy populations matched for age, sex, and ethnicity. Genotype distribution among the controls of all included studies was in agreement with HWE. Detailed characteristics of the included studies are summarized in Table 1 .
Results of meta-analysis
Evaluation of the association between CYP3A5 * 3 heterozygous mutant and ALL risk in children
The heterogeneity test of heterozygous mutant showed χ 2 = 3.03, p = 0.55, indicating that there was no significant heterogeneity among these studies. The fixed-effects model was used to calculate the pooled OR and 95% CI, which were 1.47 (0.97-2.21), Z = 1.82, p = 0.07, suggesting that there was no significant association between CYP3A5 * 3 heterozygous mutant and ALL risk in children [ Figure 2] .
Evaluation of the association between CYP3A5 * 3 homozygous mutant and ALL risk in children
The heterogeneity test of homozygous mutant showed χ 2 = 23.82, p < 0.0001, I 2 = 83%, indicating that there was significant heterogeneity among these studies. The random-effects model was used to calculate the pooled OR and 95% CI, which were 1.05 (0.62-1.79), Z = 0.18, p = 0.86, suggesting that there was no significant association between CYP3A5 * 3 homozygous mutant and ALL risk in children [ Figure 3 ].
Evaluation of the association between CYP3A5 * 3 (heterozygous + homozygous) mutant and ALL risk in children.
The heterogeneity test of (heterozygous + homozygous) mutant showed χ 2 = 8.57, p = 0.07, indicating that there was no significant heterogeneity among these studies. The fixed-effects model was used to calculate the pooled OR and 95% CI, which were 1.67 (1.14-2.44), Z = 2.63, p = 0.009, suggesting that there was significant association between CYP3A5 * 3 (heterozygous + homozygous) mutant and ALL risk in children [ Figure 4 ].
A subgroup analysis was also performed by specific ethnicity. The results of meta-analysis of CYP3A5 * 3 heterozygous, homozygous, and (heterozygous + homozygous) mutant and children with ALL in Asian populations showed the values of Z = 1.02, 0.01, and 1.34, respectively, with all p values being > 0.05 [ Figures 2-4 
Publication bias and sensitivity analysis
Publication bias was assessed through funnel plot, which provides a visual sense of the relationship between effect size and precision for publication bias among the studies included in the meta-analysis. Results showed that all points in the funnel plots were symmetrically distributed, suggesting that no significant bias was detected by funnel plot. Sensitivity analysis, in which the pooled ORs were calculated after omission of one study with the smallest sample size, revealed that the combined estimates remained virtually the same, suggesting the robustness of our results (data not shown).
DISCUSSION
A variety of factors might be involved in the development of ALL, including chemical substances, physical factors, and exposure to virus. [3, 22] Molecular epidemiological studies have suggested that genetic polymorphisms may play an important role in the etiology of ALL, and genetic variations of xenobiotic-metabolizing enzymes have been proved to influence the risk of this disease. [2] [3] [4] The human CYP3A5 gene is located on chromosome 7q21.1 and spans approximately 32 kb in length. [23] CYP3A5 is a member of the CYP3A subfamily which metabolizes approximately 50% of therapeutic drugs, steroid hormones, and extensive xenobiotics. [8] CYP3A5 genetic polymorphisms exhibit inter-individual differences in CYP3A5 expression. So far, at least 34 SNPs of CYP3A5 gene have been identified. [24] Among them, the most frequent and functional polymorphism is the A to G transition in intron 3, which has been named CYP3A5 * 3 polymorphism. The CYP3A5 * 3 allele results in a truncated protein with loss of CYP3A5 expression and enzyme activity. Individuals carrying CYP3A5 * 3 allele show slower than average metabolism of CYP3A substrates. Remarkable inter-ethnic variations in the frequencies of alleles and genotypes for the CYP3A5 * 3 polymorphism have been reported, for instance, the CYP3A5 * 3 variant allele is more frequent in Dutch Caucasians (91.7%) than in Chinese (57.9%) and is much less common in African Americans (47.5%). [8, 10, 19, 24] It is suggested that the CYP3A5 is an important genetic contributor to inter-individual differences in CYP3A-dependent metabolism. Therefore, the CYP3A5 * 3 genetic polymorphism is associated with cancer risk. However, there are conflicting findings for CYP3A5 * 3 polymorphism and the risk of ALL in children. Borst et al. investigated the impact of the CYP3A5 * 3 variant on the risk of childhood ALL and demonstrated an increased risk to develop the disease compared to the wild allele. [17] In contrast, Pakakasama et al. did not detect significant differences of genotype or allele frequencies for CYP3A5 * 3 polymorphism between ALL and control groups. [21] In the current meta-analysis, we examined the possible association between CYP3A5 * 3 polymorphism and ALL risk in children. The results we obtained were that the pooled ORs with 95% CIs of CYP3A5 * 3 heterozygous mutant, homozygous mutant, and (heterozygous + homozygous) mutant were 1.47 (0.97-2.21), 1.05 (0.62-1.79), and 1.67 (1.14-2.44) with p = 0.07, 0.86, and 0.009, respectively, indicating that there was significant association between CYP3A5 * 3 (heterozygous + homozygous) mutant and the risk of ALL in children. The results of subgroup analysis showed that the CYP3A5 * 3 (heterozygous + homozygous) mutant was associated with the development of ALL in Caucasian children (Z = 2.51, p = 0.01), but not with the risk of ALL in Asian children (Z = 1.34, p = 0.18). No significant publication bias was detected by funnel plot, and sensitivity analysis suggested the robustness of present results.
Conclusions
In summary, our meta-analysis showed that there was association between CYP3A5 * 3 polymorphism and the altered risk of ALL in children, especially in Caucasian populations. These comprehensive results deeply enhance our knowledge of the etiology of childhood ALL, which not only evaluate the risk of childhood ALL in order to protect vulnerable populations but also offer potential targets for therapeutics. However, since limited sample cases were included in this study, and selection bias as well as potential confounders (e.g., sex, ethnicity, and exposures) might influence the combined results, studies with larger sample sizes and better study designs are required in future to confirm the findings of the present study, providing further insights into the etiology and targeted prevention of ALL in children. TaqMan assay  616  203  6  89  521  0  21  182  Yes  Huang  2007  China  Asian  PCR-RFLP  91  120  11  27  53  30  41  49  Yes  Liu  2012  China  Asian  PCR-RFLP  52  120  3  23  26  7  44  49  Yes  Pakakasama  2005  Thailand  Asian  PCR-RFLP  107  320  12  58  37  32  148  140  Yes  Silveira  2012  Brazil  Caucasian  PCR-RFLP  204  364  10  65  129  46  143  173  Yes Abbreviations: PCR-RFLP: Polymerase chain reaction-restriction fragment length polymorphism; HWE: Hardy-Weinberg equilibrium
